<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet13282</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-13282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Взаимосвязи гиперурикемии, инсулинорезистентности и стадийности ожирения</article-title><trans-title-group xml:lang="en"><trans-title>Interrelationships of hyperuricemia, insulin resistance, and stages of obesity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0592-2616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Красивина</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasivina</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Красивина Ирина Геннадьевна, д.м.н., заведующий кафедрой эндокринологии</p><p>Ярославль</p><p>Researcher ID: PDY-4929-2025</p><p>Scopus ID: 8937644800</p></bio><bio xml:lang="en"><p>Irina G.Krasivina, MD</p><p>Yaroslavl</p><p>Researcher ID: PDY-4929-2025</p><p>Scopus ID: 8937644800</p></bio><email xlink:type="simple">ikrasivina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2181-9325</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгов</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgov</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгов Николай Владимирович, терапевт</p><p>Ярославль</p><p>Researcher ID: PDY-4132-2025</p><p>Scopus ID: 57221997910</p></bio><bio xml:lang="en"><p>Nikolai V. Dolgov</p><p>Yaroslavl</p><p>Researcher ID: PDY-4132-2025</p><p>Scopus ID: 57221997910</p></bio><email xlink:type="simple">dolgov64942@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0244-9699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгова</surname><given-names>Л. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgova</surname><given-names>L. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Долгова Лидия Николаевна, д.м.н., заместитель главного врача; доцент кафедры поликлинической терапии, клинической лабораторной диагностики и медицинской биохимии</p><p>150000, Ярославль, ул. Революционная, д. 5 </p><p>Researcher ID: PDY-2960-2025</p><p>Scopus ID: 23992161700</p></bio><bio xml:lang="en"><p>Lidiia N. Dolgova, MD</p><p>5 Revolyutsionnaya street, 150000, Yaroslavl</p><p>Researcher ID: PDY-2960-2025</p><p>Scopus ID: 23992161700</p></bio><email xlink:type="simple">L.Dolgova@dkb.yar.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пятовская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pyatovskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пятовская Екатерина Андреевна, терапевт</p><p>150031, Ярославль, Суздальское ш., д. 21</p><p>Researcher ID: PDY-3690-2025</p></bio><bio xml:lang="en"><p>Ekaterina A. Pyatovskaya</p><p>Yaroslavl</p><p>Researcher ID: PDY-3690-2025</p></bio><email xlink:type="simple">Sun.shine@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Частное учреждение здравоохранения «Клиническая больница «РЖД-Медицина» город Ярославль»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Private Healthcare Institution "Clinical Hospital "RZD-Medicine" city of Yaroslavl"</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РФ; Частное учреждение здравоохранения «Клиническая больница «РЖД-Медицина» город Ярославль»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Health of the Russian Federation; Private Healthcare Institution "Clinical Hospital "RZD-Medicine" city of Yaroslavl"</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>02</month><year>2026</year></pub-date><volume>22</volume><issue>4</issue><fpage>297</fpage><lpage>305</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Красивина И.Г., Долгов Н.В., Долгова Л.Н., Пятовская Е.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Красивина И.Г., Долгов Н.В., Долгова Л.Н., Пятовская Е.А.</copyright-holder><copyright-holder xml:lang="en">Krasivina I.G., Dolgov N.V., Dolgova L.N., Pyatovskaya E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/13282">https://www.omet-endojournals.ru/jour/article/view/13282</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Ожирение и гиперурикемия (ГУ) как метаболически и генетически сходные состояния с единым перечнем коморбидных заболеваний вызывают серьезную озабоченность мирового научного сообщества.</p></sec><sec><title>Цель</title><p>Цель. Оценка встречаемости ГУ и выраженности инсулинорезистентности при разных вариантах содержания жира в сопоставлении степеней ИМТ и стадийности ожирения у работающих пациентов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В одномоментное одноцентровое поперечное исследование включено 458 работающих пациентов, наблюдающихся в ЧУЗ «КБ «РЖД-Медицина» город Ярославль. Регистрировались ИМТ, результаты лабораторного исследования крови (уровень глюкозы, мочевой кислоты, триглицеридов, холестерина, липопротеидов высокой плотности), данные о имеющихся хронических заболеваниях, фотоплетизмографический маркер инсулинорезистентности. Стадию ожирения определяли на основании наличия/отсутствия гипергликемии натощак, гипертриглицеридемии, снижения ХСЛПВП, данных о коморбидности. Статистическая обработка результатов проведена с использованием программы Statistica13.</p></sec><sec><title>Результаты</title><p>Результаты. Оценка ожирения по стадиям ABCD продемонстрировала преобладание метаболически нездорового ожирения (ОЖ 1 и 2 стадии) у 64,8% пациентов (ОЖ1 — у 40,8% испытуемых и ОЖ 2 — 24,0%). ГУ встречается при метаболически нездоровом ожирении чаще при второй стадии, чем при первой у мужчин в 2,2 раза, у женщин в 2,7 раза, а относительно лиц с нормальной массой тела это соотношение составляет 5,6 и 9,04 раза. Фотоплетизмографический маркер инсулинорезистентности увеличивался от группы с нормальной массой тела до ОЖ 2 стадии. Патологический уровень фотоплетизмографического маркера инсулинорезистентности у мужчин с ОЖ 2 стадии обнаруживался чаще в 1,4 раза по сравнению с ОЖ 0 и в 2,25 раза относительно ОЖ1 стадии, у женщин — соответственно в 2,2 и 2,1 раза.</p></sec><sec><title>Заключение</title><p>Заключение. Метаболически нейтральное накопление жировой массы (избыточная масса тела и ожирение 0 стадии) в современной популяции амбулаторных работающих пациентов встречается очень редко (5,4–3,35% соответственно). Суррогатные маркеры инсулинорезистентности определяются уже при метаболически нейтральных вариантах накопления избытка жировой ткани и достигают распространенности более 50% при ожирении 2 стадии. ГУ практически не встречается при метаболически нейтральных вариантах избыточного содержания жира в организме и может выступать в качестве дешевого рутинного маркера метаболического неблагополучия и критерия эффективности профилактических вмешательств.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: Obesity and hyperuricemia (HU) as metabolically and genetically similar conditions with a single list of comorbid diseases are of serious concern to the global scientific community.</p></sec><sec><title>AIM</title><p>AIM: to assess the incidence of GU and the severity of insulin resistance with different levels of fat content in comparison with BMI levels and obesity stages in working patients.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: A cross-sectional, single-center study included 458 working patients observed in the private healthcare institution "KB "RZhD-Medicine" in Yaroslavl. BMI, laboratory blood test results (glucose, uric acid, triglycerides, cholesterol, high-density lipoproteins), data on existing chronic diseases, and a photoplethysmographic marker of insulin resistance were recorded. The obesity stage was determined based on the presence/absence of fasting hyperglycemia, hypertriglyceridemia, decreased HDL-C, and comorbidity data. Statistical processing of the results was performed using the Statistica13 program.</p></sec><sec><title>RESULTS</title><p>RESULTS: Assessment of obesity by ABCD stages demonstrated the prevalence of metabolically unhealthy obesity (OB stages 1 and 2) in 64.8% of patients (OB1 — in 40.8% of subjects and OB 2 — 24.0%). HU occurs in metabolically unhealthy obesity more often at the second stage than at the first in men by 2.2 times, in women by 2.7 times, and relative to individuals with normal body weight, this ratio is 5.6 and 9.04 times. Photoplethysmographic marker of insulin resistance increased from the group with normal body weight to OB stage 2. Pathological level of photoplethysmographic marker of insulin resistance in men with OB stage 2 was detected more often by 1.4 times compared to OB 0 and by 2.25 times relative to OB stage 1, in women — by 2.2 and 2.1 times, respectively.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: Metabolically neutral accumulation of fat mass (overweight and obesity stage 0) is very rare in the modern population of outpatient working patients (5.4–3.35%, respectively). Surrogate markers of insulin resistance are determined even with metabolically neutral variants of excess adipose tissue accumulation and reach a prevalence of more than 50% in stage 2 obesity. Hyperuricemia is practically not found in metabolically neutral variants of excess body fat and can act as a cheap routine marker of metabolic distress and a criterion for the effectiveness of preventive interventions.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гиперурикемия</kwd><kwd>ожирение</kwd><kwd>инсулинорезистентность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hyperuricemia</kwd><kwd>obesity</kwd><kwd>insulin resistance</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена по инициативе авторов без привлечения финансирования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Мазуров В.И., Мартынов А.И. и др. Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике. // Кардиоваскулярная терапия и профилактика. — 2024. — Т.23. — №1. — С.3737. doi: https://doi.org/10.15829/1728-8800-2024-3737</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Mazurov VI, Martynov AI, et al. Consensus for physicians on the management of patients with asymptomatic hyperuricemia in general therapeutic practice. Cardiovascular Therapy and Prevention. 2024;23(1):3737. (In Russ.) doi: https://doi.org/10.15829/1728-8800-2024-3737</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fan J, Bian C, Wang J, et al. Correlation Between Metabolic Syndrome and Hyperuricemia: A Systematic Review and Meta-analysis. Am J Hypertens. 2025;38(7):485-497. doi: https://doi.org/10.1093/ajh/hpaf031</mixed-citation><mixed-citation xml:lang="en">Fan J, Bian C, Wang J, et al. Correlation Between Metabolic Syndrome and Hyperuricemia: A Systematic Review and Meta-analysis. Am J Hypertens. 2025;38(7):485-497. doi: https://doi.org/10.1093/ajh/hpaf031</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wen ZY, Wei YF, Sun YH, Ji WP. Dietary pattern and risk of hyperuricemia: an updated systematic review and metaanalysis of observational studies. Front Nutr. 2024;11:1218912. doi: https://doi.org/10.3389/fnut.2024.1218912</mixed-citation><mixed-citation xml:lang="en">Wen ZY, Wei YF, Sun YH, Ji WP. Dietary pattern and risk of hyperuricemia: an updated systematic review and metaanalysis of observational studies. Front Nutr. 2024;11:1218912. doi: https://doi.org/10.3389/fnut.2024.1218912</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Yi S, Jiang W, Gong M. Exploring the Relationship Between Different Obesity Metabolism Indices and Hyperuricemia in Patients with Hypertension and Coronary Heart Disease. Diabetes Metab Syndr Obes. 2024;17:3817-3832. doi: https://doi.org/10.2147/DMSO.S491255</mixed-citation><mixed-citation xml:lang="en">Li Y, Yi S, Jiang W, Gong M. Exploring the Relationship Between Different Obesity Metabolism Indices and Hyperuricemia in Patients with Hypertension and Coronary Heart Disease. Diabetes Metab Syndr Obes. 2024;17:3817-3832. doi: https://doi.org/10.2147/DMSO.S491255</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Самородская И.В., Старинская М.А., Ким О.Т., Неймарк А.Е. Ожирение: оценка и тактика ведения пациентов. Коллективная монография. М.: ФГБУ “НМИЦ ТПМ” Минздрава России; ООО “Силицея-Полиграф”. 2021. — 174 с. https://org.gnicpm.ru/wp-content/uploads/2023/02/8.5-ozhirenie-taktika-vedeniya-paczientov.pdf</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Samorodskaya IV, Starinskaya MA, Kim OT, Nejmark AE. Ozhirenie: ocenka i taktika vedeniya pacientov. Kollektivnaya monografiya. M.: FGBU “NMIC TPM” Minzdrava Rossii; OOO “Siliceya-Poligraf”. 2021. — 174 s. (In Russ.) https://org.gnicpm.ru/wp-content/uploads/2023/02/8.5-ozhirenie-taktika-vedeniya-paczientov.pdf</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шабалин В.В., Гринштейн Ю.И., Руф Р.Р., Самсонов Н.С. Бессимптомная гиперурикемия: очевидное, спорное, гипотетическое. // Профилактическая медицина. — 2023. — Т. 26. — №7. — С. 103 109. doi: https://doi.org/10.17116/profmed202326071103</mixed-citation><mixed-citation xml:lang="en">Shabalin VV, Grinstein YuI, Ruf RR, Samsonov NS. Asymptomatic hyperuricemia: obvious, controversial, hypothetical. Russian Journal of Preventive Medicine. 2023;26(7):103 109. (In Russ.) doi: https://doi.org/10.17116/profmed202326071103</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Donini LM, Pinto A, Giusti AM, et al. Obesity or BMI Paradox? Beneath the Tip of the Iceberg. Frontiers in Nutrition. 2020;7:53. doi: https://doi.org/10.3389/fnut.2020.00053</mixed-citation><mixed-citation xml:lang="en">Donini LM, Pinto A, Giusti AM, et al. Obesity or BMI Paradox? Beneath the Tip of the Iceberg. Frontiers in Nutrition. 2020;7:53. doi: https://doi.org/10.3389/fnut.2020.00053</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова Н.И., Ганенко Л.А., Поркшеян М.И. Метаболически здоровое ожирение – что мы о нем? // Медицинский вестник Юга России. — 2017. — Т.8. — №3. — С.6-16. doi: https://doi.org/10.21886/2219-8075-2017-8-3-6-16</mixed-citation><mixed-citation xml:lang="en">Volkova NI, Ganenko LA, Porksheyan MI. Metabolic healthy obtsity, what do we know about it? Medical Herald of the South of Russia. 2017;8(3):6-16. (In Russ.) doi: https://doi.org/10.21886/2219-8075-2017-8-3-6-16</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Мустафина C.В., Щербакова Л.В., Козупеева Д.А. и др. Распространенность метаболически здорового ожирения по данным эпидемиологического обследования выборки 45–69 лет г. Новосибирска. // Ожирение и метаболизм. — 2018. — Т.15. — №4. — С. 31-37. doi: https://doi.org/10.14341/omet9615</mixed-citation><mixed-citation xml:lang="en">Mustafina SV, Shcherbakova LV, Kozupeeva DA et al. Тhe prevalence of metabolically healthy obesity: data from the epidemiological survey in of Novosibirsk. Obesity and metabolism. 2018;15(4):31-37. (In Russ.) doi: https://doi.org/10.14341/omet9615</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Garvey WT, Garber AJ, Mechanick JI, et al. The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977- 89. doi: https://doi.org/10.4158/EP14280.PS</mixed-citation><mixed-citation xml:lang="en">Garvey WT, Garber AJ, Mechanick JI, et al. The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977- 89. doi: https://doi.org/10.4158/EP14280.PS</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mechanick JI, Hurley DL, Garvey WT. Adiposity-Based Chronic Disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. Endocr Pract. 2017;23(3):372-378. doi: https://doi.org/10.4158/EP161688.PS</mixed-citation><mixed-citation xml:lang="en">Mechanick JI, Hurley DL, Garvey WT. Adiposity-Based Chronic Disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. Endocr Pract. 2017;23(3):372-378. doi: https://doi.org/10.4158/EP161688.PS</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Самородская И.В, Болотова Е.В., Бойцов С.А. Актуальные вопросы классификации ожирения. // Кардиоваскулярная терапия и профилактика. — 2015. — Т. 14. — №4. — С. 103–110 doi: https://doi.org/10.15829/1728-8800-2015-4-103-110</mixed-citation><mixed-citation xml:lang="en">Samorodskaya IV, Bolotova EV, Boytsov SA. Current issues of obesity classification. Cardiovascular Therapy and Prevention. 2015;14(4):103-110. (In Russ.) doi: https://doi.org/10.15829/1728-8800-2015-4-103-110</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В., Барыкина И.Н., Саласюк А.С. Национальные клинические рекомендации по ожирению: концепция и перспективы. // Вестник ВолгГМУ. — 2017. — Т. 1. — №61. — С.134-140</mixed-citation><mixed-citation xml:lang="en">Nedogoda SV, Barykina IN, Salasyuk AS. National Clinical Guidelines on Obesity: Concept and Prospects. Vestnik VolgGMU. 2017;1(61):134-140 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года. // Вестник репродуктивного здоровья. — 2025. — Т.4. — №2. — С.14-30 doi: https://doi.org/10.14341/brh12763</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mokrysheva NG, Melnichenko GA, Troshina EA, Mazurina NV, Ershova EV, et al. Clinical recommendations «Gestational diabetes mellitus» of the Russian Ministry of Health. Version of the year 2024. Bulletin of Reproductive Health. 2025;4(2):14-30. (In Russ.) doi: https://doi.org/10.14341/brh12763</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nieto-Martínez R, González-Rivas JP, Ugel E, et al. Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: the VEMSOLS STUDY results. Endocr Pract. 2018;24(1):6-13. doi: https://doi.org/10.4158/EP161644.OR</mixed-citation><mixed-citation xml:lang="en">Nieto-Martínez R, González-Rivas JP, Ugel E, et al. Application of the AACE/ACE advanced framework for the diagnosis of obesity and cardiometabolic disease staging in a general population from 3 regions of Venezuela: the VEMSOLS STUDY results. Endocr Pract. 2018;24(1):6-13. doi: https://doi.org/10.4158/EP161644.OR</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez-Rivas JP, Mechanick JI, Hernandez JP, et al. Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic: The Kardiovize study. Obes Sci Pract. 2021;7(5):535-544. doi: https://doi.org/10.1002/osp4.496</mixed-citation><mixed-citation xml:lang="en">Gonzalez-Rivas JP, Mechanick JI, Hernandez JP, et al. Prevalence of adiposity-based chronic disease in middle-aged adults from Czech Republic: The Kardiovize study. Obes Sci Pract. 2021;7(5):535-544. doi: https://doi.org/10.1002/osp4.496</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">González-Salazar LE, Serralde-Zúñiga AE, Flores-López A, et al Prevalence of adiposity-based chronic disease and its association with anthropometric and clinical indices: a cross-sectional study. Br J Nutr. 2023;130(1):93-102. doi: https://doi.org/10.1017/S0007114522002963</mixed-citation><mixed-citation xml:lang="en">González-Salazar LE, Serralde-Zúñiga AE, Flores-López A, et al Prevalence of adiposity-based chronic disease and its association with anthropometric and clinical indices: a cross-sectional study. Br J Nutr. 2023;130(1):93-102. doi: https://doi.org/10.1017/S0007114522002963</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Panlu K, Zhou Z, Huang L, et al. Associations between obesity and hyperuricemia combing mendelian randomization with network pharmacology. Heliyon. 2024;10(6):e27074. doi: https://doi.org/10.1016/j.heliyon.2024.e27074</mixed-citation><mixed-citation xml:lang="en">Panlu K, Zhou Z, Huang L, et al. Associations between obesity and hyperuricemia combing mendelian randomization with network pharmacology. Heliyon. 2024;10(6):e27074. doi: https://doi.org/10.1016/j.heliyon.2024.e27074</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Лавренова Е.А., Драпкина О.М. Инсулинорезистентность при ожирении: причины и последствия. // Ожирение и метаболизм. — 2020. — Т.17. — №1. — С.48-55. doi: https://doi.org/10.14341/omet9759</mixed-citation><mixed-citation xml:lang="en">Lavrenova EA, Drapkina OM. Insulin resistance in obesity: pathogenesis and effects. Obesity and metabolism. 2020;17(1):48-55. (In Russ.). doi: https://doi.org/10.14341/omet9759</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">De Souza AL, Batista GA, Alegre SM. Assessment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: Comparison with the spectral analysis of photoplethysmography. J Diabetes Complications. 2017;31(1):128-133. doi: https://doi.org/10.1016/j.jdiacomp.2016.10.018</mixed-citation><mixed-citation xml:lang="en">De Souza AL, Batista GA, Alegre SM. Assessment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: Comparison with the spectral analysis of photoplethysmography. J Diabetes Complications. 2017;31(1):128-133. doi: https://doi.org/10.1016/j.jdiacomp.2016.10.018</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ройтберг Г.Е., Дорош Ж.В., Шархун О.О. и др. Возможности применения нового метаболического индекса для оценки инсулинорезистентности в клинической практике. // Рациональная фармакотерапия в кардиологии. — 2014. — Т.10. — №3. — С.264-274. doi: https://doi.org/10.20996/1819-6446-2014-10-3-264-274</mixed-citation><mixed-citation xml:lang="en">Roytberg GE, Dorosh JV, Sharkhun OO, et al. New metabolic index use potentialities in evalution of insulin resistance in clinical practice. Rational Pharmacotherapy in Cardiology. 2014;10(3):264-274. (In Russ.) doi: https://doi.org/10.20996/1819-6446-2014-10-3-264-274</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
